SPRO
Spero Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.21
−0.82%Forward multiples
Based on analyst estimates
- P/E forward
- —
- P/E 2026E
- —
- P/E 2027E
- 1.80x
- P/E 2028E
- —
- P/S forward
- —
Trailing multiples
Trailing twelve months
- P/E TTM
- 8.64x
- PEG TTM
- —
- Price / book
- 1.59x
- Price / sales
- 1.64x
- Price / cash flow
- 3.60x
Enterprise value
- Enterprise value
- $21.7M
- EV / sales
- 0.51x
- EV / EBITDA
- 2.82x
- EV / EBIT
- 3.61x
- Market cap
- $70.5M
Trailing, forward and enterprise-value multiples for the requested listing · Data as of Jun 1, 2026